Liposomal bortezomib is active against chronic myeloid leukemia by disrupting the Sp1-BCR/ABL axis

The abundance of the BCR/ABL protein critically contributes to CML pathogenesis and drug resistance. However, understanding of molecular mechanisms underlying BCR/ABL gene regulation remains incomplete. While BCR/ABL kinase inhibitors have shown unprecedented efficacy in the clinic, most patients re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Yang, Xiaojuan, Pang, Jiuxia, Shen, Na, Yan, Fei, Wu, Lai-Chu, Al-Kali, Aref, Litzow, Mark R., Peng, Yong, Lee, Robert J., Liu, Shujun
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5095007/
https://ncbi.nlm.nih.gov/pubmed/27144331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8871
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados